
|Articles|May 15, 2003
Artificial tear protects and lasts to improve dry eye signs
Author(s)Cheryl Guttman
Clinical practice experience is confirming the results from premarketing clinical trials that showed a new over-the-counter artificial tear product (Systane, Alcon) is a novel approach for modulating the signs and symptoms of dry eye.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
2
Moorfields study reveals sharp rise in glaucoma burden across the UK
3
Nanoscope’s gene therapy, MCO-010 receives Sakigake and Orphan Drug Designations in Japan
4
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
5














































